Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Christopher Murphy

Podiatrist, Foot & Ankle Surgery Edgewater, FL Doctor of Podiatric Medicine

NPI 1760463848 CMS profile 79366

107 Merrimac St, Edgewater, FL 32132

Open in the dashboard

General payments

$2,752

20 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Murphy of Edgewater, FL is reported in the CMS Open Payments database as having received $2,752 across 20 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 52nd percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $258 5
2024 General $15 1
2023 General $41 1
2022 General $21 1
2021 General $1,369 4
2019 General $1,049 8

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Murphy
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Christopher Murphy were reported at $258. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Christopher Murphy Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $1,049 $389 $118–$1,406 $163
2020 $0 $191 $62–$691 $114
2021 $1,369 $329 $104–$1,341 $132
2022 $21 $419 $125–$1,611 $149
2023 $41 $377 $128–$1,164 $160
2024 $15 $394 $134–$1,168 $164
2025 $258 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $2,199 7 payments
  2. Smith+Nephew, Inc. $265 7 payments
  3. Pacira Pharmaceuticals Incorporated $92 1 payment
  4. Merck Sharp & Dohme Corporation $90 1 payment
  5. Paragon 28, Inc. $79 2 payments
  6. Paratek Pharmaceuticals, Inc. $18 1 payment
  7. Organogenesis Inc. $10 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $2,006 2 payments
  2. Food and Beverage $598 17 payments
  3. Travel and Lodging $148 1 payment
Products named General payments · program years 2019–2025
  1. GRAFIX PL Other Advanced Wound Management $162 2 payments
  2. EXPAREL $92 1 payment
  3. SIVEXTRO $90 1 payment
  4. GRAFIX PL Other Advanced Wound Management $55 2 payments
  5. BABY GORILLA $52 1 payment
  6. Hammertube Sterile Implant Kits $27 1 payment
  7. Santyl $27 2 payments
  8. Bone Anchors with Arthroscopic Delivery System $21 1 payment
  9. NUZYRA $18 1 payment
  10. Apligraf $10 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

45

Median for Podiatry: 160

Drug cost

$266

Median for Podiatry: $2,368

Branded share of claims

0%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxycycline Hyclate Generic 21 $160
Cephalexin Generic 24 $106

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$283,893

Of which drugs: $96

Medicare patients

362

Average age 78

Services billed

3,962

202 women, 160 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Ischemic heart disease 37%
Chronic kidney disease 36%
Diabetes 33%
COPD 29%
Atrial fibrillation 27%
Depression 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 40 mg J1030 Office 12 13 $51
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 39 57 $42
Injection, methylprednisolone acetate, 1 mg J1010 Office 25 35 $4

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

20 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record